Identification

Name
Aminocaproic Acid
Accession Number
DB00513  (APRD00791, EXPT00408, EXPT00461, DB04134)
Type
Small Molecule
Groups
Approved, Investigational
Description

An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties. [PubChem]

Structure
Thumb
Synonyms
  • 6-Aminocaproic acid
  • 6-aminohexanoic acid
  • Acide aminocaproïque
  • Acide aminocaproque
  • Ácido aminocapróico
  • Acidum Aminocaproicum
  • Ahx
  • AMINOCAPROIC
  • Aminocaproic acid
  • Aminocapronsäure
  • Aminohexanoic acid
  • Caproamin
  • Eaca
  • EACA
  • Epsicaprom
  • Epsilcapramine
  • epsilon-Ahx
  • Epsilon-Aminocaproic Acid
  • epsilon-Aminohexanoic acid
  • Z
External IDs
177 J.D. / CL 10304 / CL-10304 / CY 116 / CY-116 / JD 177 / NSC-26154
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AmicarTablet500 mg/1OralClover Pharmaceuticals Corp.2015-06-01Not applicableUs
AmicarTablet1000 mg/1OralClover Pharmaceuticals Corp.2015-06-01Not applicableUs
AmicarTablet500 mg/1OralAvera Mc Kennan Hospital2015-09-23Not applicableUs
AmicarSolution.25 g/mLOralClover Pharmaceuticals Corp.2015-06-01Not applicableUs
Aminocaproic AcidTablet1000 mg/1OralVersa Pharm Incorporated2012-06-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aminocaproic AcidInjection, solution250 mg/mLIntravenousAmerican Regent1990-09-30Not applicableUs
Aminocaproic AcidInjection, solution250 mg/mLIntravenousHospira, Inc.1987-03-09Not applicableUs
Aminocaproic AcidSyrup.25 g/mLOralVersa Pharm Incorporated2000-03-01Not applicableUs
Aminocaproic AcidTablet500 mg/1OralVersa Pharm Incorporated2001-08-01Not applicableUs
International/Other Brands
Acepramin (Pannonpharma) / AMICAR / Amocap (Celon) / Caproamin (Rottapharm) / Caprocat (Catalysis) / Caprolisin (Menarini) / E-Capro (Edruc) / Epsicaprom / Hemocid (GlaxoSmithKline) / Inselon (Ying Yuan) / Ipron (Johnson) / Ipsilon (Nikkho) / Kai Nai Yin (Wuxi) / Minocap (ACI) / Plaslloid (CCPC) / Resplamin (Shinlin Sinseng)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Exoden White ToothAminocaproic Acid (.3 g/150g) + Silicon dioxide (7.5 g/150g)PasteTopicalLifeon Corp.2016-04-07Not applicableUs
NAVI Black and C-ClinicAminocaproic Acid (.12 g/120g) + Calcium Carbonate (48 g/120g) + Calcium phosphate, dibasic, dihydrate (.12 g/120g)PasteDentalEq Maxon Corp.2013-04-01Not applicableUs
SolmeetAminocaproic Acid (.05 g/100g) + Alcloxa (.05 g/100g) + Calcium Carbonate (15.85 g/100g) + Calcium phosphate, dibasic, dihydrate (.6 g/100g)Paste, dentifriceDentalSolbin Co., Ltd2010-12-15Not applicableUs
SolmeetAminocaproic Acid (.05 g/100g) + Alcloxa (.05 g/100g) + Calcium Carbonate (15.85 g/100g) + Calcium phosphate, dibasic, dihydrate (.6 g/100g)Paste, dentifriceDentalSolbin Co., Ltd2010-12-15Not applicableUs
Solmeet denti doctorAminocaproic Acid (.05 g/100g) + Alcloxa (.05 g/100g) + Calcium Carbonate (15.85 g/100g) + Calcium phosphate, dibasic, dihydrate (.6 g/100g)Paste, dentifriceDentalSolbin Co., Ltd2010-12-15Not applicableUs
Solmeet denti doctorAminocaproic Acid (.05 g/100g) + Alcloxa (.05 g/100g) + Calcium Carbonate (15.85 g/100g) + Calcium phosphate, dibasic, dihydrate (.6 g/100g)Paste, dentifriceDentalSolbin Co., Ltd2010-12-15Not applicableUs
Categories
UNII
U6F3787206
CAS number
60-32-2
Weight
Average: 131.1729
Monoisotopic: 131.094628665
Chemical Formula
C6H13NO2
InChI Key
SLXKOJJOQWFEFD-UHFFFAOYSA-N
InChI
InChI=1S/C6H13NO2/c7-5-3-1-2-4-6(8)9/h1-5,7H2,(H,8,9)
IUPAC Name
6-aminohexanoic acid
SMILES
NCCCCCC(O)=O

Pharmacology

Indication

For use in the treatment of excessive postoperative bleeding.

Structured Indications
Pharmacodynamics

Aminocaproic acid works as an antifibrinolytic. It is a derivative of the amino acid lysine. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. Aminocaproic acid may be a possible prophylactic for vascular disease, as it may prevent formation of lipoprotein (a), a risk factor for vascular disease.

Mechanism of action

Aminocaproic acid binds reversibly to the kringle domain of plasminogen and blocks the binding of plasminogen to fibrin and its activation to plasmin. With NO activation of plasmin, there is a reduction in fibrinolysis. This consequently will reduce the amount of bleeding post surgery. Elevated plasma levels of lipoprotein(a) have been shown to increase the risk of vascular disease. Lipoprotein 9a)a has two components, apolipoprotein B-100, linked to apolipoprotein (a). Aminocaproic acid may change the conformation of apoliprotein (a), changing its binding properties and potentially preventing the formation of lipoprotein (a).

TargetActionsOrganism
APlasminogen
inhibitor
Human
ATissue-type plasminogen activator
antagonist
Human
UApolipoprotein(a)
other
Human
Absorption

Absorbed rapidly following oral administration. In adults, oral absorption appears to be a zero-order process with an absorption rate of 5.2 g/hr. The mean lag time in absorption is 10 minutes. After a single oral dose of 5 g, absorption was complete (F=1).

Volume of distribution
  • 23.1 ± 6.6 L
Protein binding
Not Available
Metabolism

Sixty-five percent of the dose is recovered in the urine as unchanged drug and 11% of the dose appears as the metabolite adipic acid.

Route of elimination

Renal excretion is the primary route of elimination, whether aminocaproic acid is administered orally or intravenously.

Half life

The terminal elimination half-life is approximately 2 hours.

Clearance
  • 169 mL/min
Toxicity

A few cases of acute overdosage with intravenous administration have been reported. The effects have ranged from no reaction to transient hypotension to severe acute renal failure leading to death. The intravenous and oral LD50 were 3.0 and 12.0 g/kg respectively in the mouse and 3.2 and 16.4 g/kg respectively in the rat. An intravenous infusion dose of 2.3 g/kg was lethal in the dog.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Aminocaproic Acid Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
Coagulation Factor IX (Recombinant)The risk or severity of adverse effects can be increased when Aminocaproic Acid is combined with Coagulation Factor IX (Recombinant).Approved
Fibrinogen HumanThe risk or severity of adverse effects can be increased when Aminocaproic Acid is combined with Fibrinogen Human.Approved
TretinoinTretinoin may increase the thrombogenic activities of Aminocaproic Acid.Approved, Investigational, Nutraceutical
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

Frantisek Mares, "Process for producing caprolactam from 6-aminocaproic acid." U.S. Patent US3988319, issued August, 1955.

US3988319
General References
Not Available
External Links
Human Metabolome Database
HMDB01901
KEGG Drug
D00160
KEGG Compound
C02378
PubChem Compound
564
PubChem Substance
46506934
ChemSpider
548
BindingDB
50357211
ChEBI
57826
ChEMBL
CHEMBL1046
Therapeutic Targets Database
DAP000200
PharmGKB
PA164774947
HET
ACA
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Aminocaproic_acid
ATC Codes
B02AA01 — Aminocaproic acid
PDB Entries
1cea / 1hpk / 1ilp / 1ilq / 1kqs / 1m90 / 1pk2 / 1vq6 / 1vq8 / 1vq9
show 29 more
FDA label
Download (152 KB)
MSDS
Download (73.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedNot AvailableAortic Diseases1
0CompletedBasic ScienceRosaceas1
1CompletedTreatmentCraniosynostosis1
1SuspendedTreatmentIntracerebral Hemorrhage1
2RecruitingPreventionBone destruction / Cancer, Breast1
2RecruitingTreatmentCraniosynostosis1
2RecruitingTreatmentHaematological Malignancies / Thrombocytopenias1
2, 3CompletedPreventionCardiopulmonary Bypass / Fibrinolysis / General Surgery / Inflammatory Reaction1
4CompletedOtherComplication of Extracorporeal Circulation / Pediatric Cardiac Surgery1
4CompletedPreventionPathologic Fibrinolysis1
4CompletedTreatmentSynovitis of osteoarthritis1
4RecruitingTreatmentBilateral Varus Rotational Osteotomy / E-Aminocaproic Acid1
4RecruitingTreatmentBlood Loss / Hip Arthritis / Knee Arthritis1
4Unknown StatusPreventionOral Hemorrhage1
4Unknown StatusTreatmentScoliosis1
Not AvailableCompletedNot AvailableSurgery, Cardiac1
Not AvailableCompletedSupportive CareHaemorrhage1
Not AvailableCompletedTreatmentKyphosis / Lordosis / Scoliosis / Spinal Stenosis / Spondylitis1
Not AvailableUnknown StatusTreatmentCardiopulmonary Bypass1

Pharmacoeconomics

Manufacturers
  • Xanodyne pharmaceutics inc
  • Abraxis pharmaceutical products
  • Baxter healthcare corp anesthesia and critical care
  • Hospira inc
  • Luitpold pharmaceuticals inc
  • Mikart inc
Packagers
Dosage forms
FormRouteStrength
SolutionOral.25 g/mL
TabletOral1000 mg/1
TabletOral500 mg/1
Injection, solutionIntravenous250 mg/mL
SyrupOral.25 g/mL
PasteTopical
PasteDental
Paste, dentifriceDental
Prices
Unit descriptionCostUnit
Amicar 1000 mg tablet7.17USD tablet
Amicar 500 mg tablet3.67USD tablet
Aminocaproic acid 500 mg tablet2.28USD tablet
Aminocaproic acid 250 mg/ml0.06USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)205 °CPhysProp
water solubility5.05E+005 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP-2.95HANSCH,C ET AL. (1995)
pKa4.43 (at 25 °C)KORTUM,G ET AL (1961)
Predicted Properties
PropertyValueSource
Water Solubility45.2 mg/mLALOGPS
logP-2.7ALOGPS
logP-2ChemAxon
logS-0.46ALOGPS
pKa (Strongest Acidic)4.73ChemAxon
pKa (Strongest Basic)10.21ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area63.32 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity34.66 m3·mol-1ChemAxon
Polarizability14.71 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Download (7.2 KB)
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (3 TMS)GC-MSsplash10-00ds-3900000000-d2bae6c296c96fbad8d6
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (3 TMS)GC-MSsplash10-00di-9700000000-96516a7056d0134fe91f
GC-MS Spectrum - GC-MS (3 TMS)GC-MSsplash10-00di-3900000000-b1e222c28c8ee5ee7e39
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-00ds-3900000000-d2bae6c296c96fbad8d6
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-00di-9700000000-96516a7056d0134fe91f
GC-MS Spectrum - GC-MSGC-MSsplash10-00di-3900000000-b1e222c28c8ee5ee7e39
MS/MS Spectrum - Quattro_QQQ 10V, N/A (Annotated)LC-MS/MSsplash10-01p9-7900000000-7b0c4a3576914da3beb0
MS/MS Spectrum - Quattro_QQQ 25V, N/A (Annotated)LC-MS/MSsplash10-014i-9100000000-6d1cca409e0604efbe03
MS/MS Spectrum - Quattro_QQQ 40V, N/A (Annotated)LC-MS/MSsplash10-0pdi-9000000000-a55855076c25405ac1e5
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, NegativeLC-MS/MSsplash10-001i-0900000000-a47431cd716ecb19b9e6
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, NegativeLC-MS/MSsplash10-001i-1900000000-a5934cb182440e097505
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, NegativeLC-MS/MSsplash10-0a4i-9100000000-fe8764f31273202c4192
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, NegativeLC-MS/MSsplash10-0a4l-9000000000-d811796a47319a78c0ac
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, NegativeLC-MS/MSsplash10-0006-9000000000-85516d2ef8e256aa32c4
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, PositiveLC-MS/MSsplash10-001i-0900000000-b263ad88d0bb4ca9e2a8
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, PositiveLC-MS/MSsplash10-02ta-9400000000-6fd9244fa9d4129efb9f
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, PositiveLC-MS/MSsplash10-014i-9000000000-e57b77ac2660e8633c45
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, PositiveLC-MS/MSsplash10-05ox-9000000000-ac37660729ea0447a3b8
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, PositiveLC-MS/MSsplash10-052f-9000000000-dd2777a39a8decd7066d
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , PositiveLC-MS/MSsplash10-02t9-8900000000-024692ea60c820275def
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-001i-0900000000-a47431cd716ecb19b9e6
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-001i-1900000000-a5934cb182440e097505
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0a4i-9100000000-fe8764f31273202c4192
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0a4l-9000000000-d811796a47319a78c0ac
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0006-9000000000-85516d2ef8e256aa32c4
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-03e9-7900000000-0ee90be04d7e3f9f2f1e
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03e9-2900000000-5a4b7c29f57f4a21bbf1
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-02ta-9400000000-538c560b9cc23892e021
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-9000000000-4b1019dc1efb41cf5840
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0ar3-9000000000-37f51bccc6d2db70f2eb
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0900000000-b263ad88d0bb4ca9e2a8
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-02ta-9400000000-f654b53d07a97f719e19
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-014i-9000000000-e57b77ac2660e8633c45
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-05ox-9000000000-f6e6dd1b173059338d41
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-052f-9000000000-dd2777a39a8decd7066d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-02t9-8900000000-bf129c99e91c701b7637
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-03di-0900000000-9ebeb85e0b04ac8791af
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0089-1900000000-5fb0d490b0c3ad9ad244
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-000i-3900000000-720496371365a1b0de2e
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as medium-chain fatty acids. These are fatty acids with an aliphatic tail that contains between 4 and 12 carbon atoms.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Fatty acids and conjugates
Direct Parent
Medium-chain fatty acids
Alternative Parents
Amino fatty acids / Straight chain fatty acids / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organic oxides / Monoalkylamines / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Medium-chain fatty acid / Amino fatty acid / Straight chain fatty acid / Amino acid or derivatives / Amino acid / Carboxylic acid derivative / Carboxylic acid / Monocarboxylic acid or derivatives / Primary amine / Organooxygen compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
omega-amino fatty acid, epsilon-amino acid (CHEBI:16586) / Amino fatty acids (C02378) / Amino fatty acids (LMFA01100035)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type peptidase activity
Specific Function
Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In...
Gene Name
PLG
Uniprot ID
P00747
Uniprot Name
Plasminogen
Molecular Weight
90568.415 Da
References
  1. Mochalkin I, Cheng B, Klezovitch O, Scanu AM, Tulinsky A: Recombinant kringle IV-10 modules of human apolipoprotein(a): structure, ligand binding modes, and biological relevance. Biochemistry. 1999 Feb 16;38(7):1990-8. [PubMed:10026282]
  2. Prandota J, Pankow-Prandota L, Kotecki L: Impaired activation of the fibrinolytic system in children with Henoch-Schonlein purpura: beneficial effect of hydrocortisone plus Sigma-aminocaproic acid therapy on disappearance rate of cutaneous vasculitis and fibrinolysis. Am J Ther. 2001 Jan-Feb;8(1):11-9. [PubMed:11304653]
  3. Lee KN, Jackson KW, McKee PA: Effect of a synthetic carboxy-terminal peptide of alpha(2)-antiplasmin on urokinase-induced fibrinolysis. Thromb Res. 2002 Feb 1;105(3):263-70. [PubMed:11927133]
  4. Sun Z, Chen YH, Wang P, Zhang J, Gurewich V, Zhang P, Liu JN: The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochim Biophys Acta. 2002 Apr 29;1596(2):182-92. [PubMed:12007600]
  5. Kanalas JJ: Analysis of plasmin binding and urokinase activation of plasminogen bound to the Heymann nephritis autoantigen, gp330. Arch Biochem Biophys. 1992 Dec;299(2):255-60. [PubMed:1280065]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serine-type endopeptidase activity
Specific Function
Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in t...
Gene Name
PLAT
Uniprot ID
P00750
Uniprot Name
Tissue-type plasminogen activator
Molecular Weight
62916.495 Da
References
  1. Husain SS, Hasan AA, Budzynski AZ: Differences between binding of one-chain and two-chain tissue plasminogen activators to non-cross-linked and cross-linked fibrin clots. Blood. 1989 Aug 15;74(3):999-1006. [PubMed:2502209]
  2. Urano T, Sator de Serrano V, Gaffney PJ, Castellino FJ: Effectors of the activation of human [Glu1]plasminogen by human tissue plasminogen activator. Biochemistry. 1988 Aug 23;27(17):6522-8. [PubMed:3146348]
  3. Tran-Thang C, Vouillamoz D, Kruithof EK, Sordat B: Human Co115 colon carcinoma cells potentiate the degradation of laminin mediated by tissue-type plasminogen activator. J Cell Physiol. 1994 Nov;161(2):285-92. [PubMed:7962113]
  4. Krishnamurti C, Vukelja SJ, Alving BM: Inhibitory effects of lysine analogues on t-PA induced whole blood clot lysis. Thromb Res. 1994 Mar 15;73(6):419-30. [PubMed:8073394]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Serine-type endopeptidase activity
Specific Function
Apo(a) is the main constituent of lipoprotein(a) (Lp(a)). It has serine proteinase activity and is able of autoproteolysis. Inhibits tissue-type plasminogen activator 1. Lp(a) may be a ligand for m...
Gene Name
LPA
Uniprot ID
P08519
Uniprot Name
Apolipoprotein(a)
Molecular Weight
501316.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Becker L, Cook PM, Koschinsky ML: Identification of sequences in apolipoprotein(a) that maintain its closed conformation: a novel role for apo(a) isoform size in determining the efficiency of covalent Lp(a) formation. Biochemistry. 2004 Aug 10;43(31):9978-88. [PubMed:15287725]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xanthine dehydrogenase activity
Specific Function
Oxidase with broad substrate specificity, oxidizing aromatic azaheterocycles, such as N1-methylnicotinamide and N-methylphthalazinium, as well as aldehydes, such as benzaldehyde, retinal, pyridoxal...
Gene Name
AOX1
Uniprot ID
Q06278
Uniprot Name
Aldehyde oxidase
Molecular Weight
147916.735 Da
References
  1. Subramanyam B, Callery PS, Geelhaar LA, Egorin MJ: A cyclic imine intermediate in the in vitro metabolic conversion of 1,6-diaminohexane to 6-aminohexanoic acid and caprolactam. Xenobiotica. 1989 Jan;19(1):33-42. [PubMed:2502880]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:38